Opinion|Videos|July 24, 2024
EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM
Author(s)Joseph Mikhael, MD
Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Results from the phase 1/2 MonumenTAL-1 study and phase 1B MonumenTAL-2 study were also presented at EHA 2024. How do the results from these two trials contribute to the evolving role of talquetamab in multiple myeloma?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact use of treatment regimens?
- What challenges must be considered and overcome with bispecific antibody-containing regimens in RRMM?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5